Why the study?
Does oral administration of novel peptidomimetic renin inhibitors (compound 38a) reduce mean arterial blood pressure in sodium-depleted marmosets?
Does oral administration of novel peptidomimetic renin inhibitors (compound 38a) reduce mean arterial blood pressure in sodium-depleted marmosets?
Novel peptidomimetic renin inhibitors, particularly compound 38a, demonstrate potent in vitro activity and oral efficacy in reducing blood pressure in a marmoset model.
Answers are grounded in this paper and cite their sources.
Supports preclinical development of oral renin inhibitors; leaves open translation to human hypertension.
The action of renin is the rate-limiting step of the renin-angiotensin system (RAS), a key regulator of blood pressure. Effective renin inhibitors directly block the RAS entirely at source and, thus, may provide a vital weapon for hypertension therapy. Our efforts toward identifying novel small-molecule peptidomimetic renin inhibitors have resulted in the design of transition-state isosteres such as 1 bearing an all-carbon 8-phenyl-octanecarboxamide framework. Optimization of the extended P3 portion of 1 and extensive P2' modifications provided analogues with improved in vitro potencies in the presence of plasma. X-ray resolution of rh-renin/38a in the course of SAR work surprisingly unveiled the exploitation of a previously unexplored pocket (S3sp) important for strong binding affinities. Several inhibitors demonstrated oral efficacy in sodium-depleted marmosets. The most potent, 38a, induced dose-dependently a pronounced reduction in mean arterial blood pressure, paralleled by complete blockade of active plasma renin, up to 8 h post-dose. Oral bioavailability of 38a was 16% in marmosets.
No takes yet. Share an insight, caveat, or question.
Göschke et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: